We are rapidly growing our development, regulatory and clinical expertise, along with world class manufacturing capabilities, to break existing oligopolies and make therapies affordable to patients globally. Biocon Biologics’ state-of-the-art manufacturing facilities are certified by various regulatory agencies from developed and emerging markets. With an unwavering commitment to quality, the Biocon Biologics has made significant investments in commercial scale, globally compliant manufacturing facilities across diverse technology platforms spanning insulin analogs, monoclonal antibodies and other recombinant proteins. We continue to expand our infrastructure in a capital-efficient, modular way.

Our biosimilars have benefitted millions of patients globally. Large-scale production of high quality, reliably supplied biosimilars requires commitment, highly specialised biologics knowledge and experience. Our facility in Malaysia is Asia’s largest integrated insulins facility that manufactures Drug Substance and Drug Products in vials, cartridges and insulin delivery devices, and markets them in Malaysia, EU and several other key emerging markets. The EU GMP certification received for Insulin Drug Substance, Drug Product and Devices facilities in August 2019 further expands Biocon Malaysia’s capacities to cater to growing market needs.